Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].
Vannata, B., Innocenti, I., Autore, F., Sora', F., Chiusolo, P., Leone, G., Sica, S., Laurenti, L., High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia, <<AMERICAN JOURNAL OF HEMATOLOGY>>, 2012; 87 (12): E133-E133. [doi:10.1002/ajh.23349] [http://hdl.handle.net/10807/40290]
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia
Vannata, Barbara;Innocenti, Idanna;Autore, Francesco;Sora', Federica;Chiusolo, Patrizia;Leone, Giuseppe;Sica, Simona;Laurenti, Luca
2012
Abstract
Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
